Will EMA approve AstraZeneca's Calquence combination for first-line MCL by end of 2025?

Will NCCN include Calquence combination in guidelines for first-line MCL by mid-2025?

Will Calquence combination show significant overall survival improvement in trials by end of 2025?

What market share will Calquence combo achieve in U.S. for first-line MCL by end of 2025?

What percentage of serious adverse events will be reported for Calquence combo by Jan 2026?

Where will Calquence combo be standard care for first-line MCL by end of 2025?